title: Reply to V. Amoroso et al.
authors.affiliation: James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: James C
authors.initials: JC
authors.lastname: Yao
authors.affiliation: James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Voi
authors.affiliation: James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Jeremie
authors.initials: J
authors.lastname: Lincy
authors.affiliation: James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Marianne
authors.initials: M
authors.lastname: Pavel
mesh_terms: D000068338:Everolimus; D006801:Humans; D010190:Pancreatic Neoplasms
chemical_list: D000068338:Everolimus